Afamelanotide for Erythropoietic Protoporphyria

2015271 citationsJournal Articlebronze Open Access

Authors

Janneke G. Langendonk · Erasmus MC

Manisha Balwani · Icahn School of Medicine at Mount Sinai

Karl E. Anderson · The University of Texas Medical Branch at Galveston

Herbert L. Bonkovsky · Wake Forest University

A. Anstey · Royal Gwent Hospital

D. Montgomery Bissell · University of California, San Francisco

Joseph R. Bloomer

Abstract

Afamelanotide had an acceptable side-effect and adverse-event profile and was associated with an increased duration of sun exposure without pain and improved quality of life in patients with erythropoietic protoporphyria. (Funded by Clinuvel Pharmaceuticals and others; ClinicalTrials.gov numbers, NCT01605136 and NCT00979745.).

Topics & Keywords

Porphyrin Metabolism and Disorders Heme Oxygenase-1 and Carbon Monoxide Neonatal Health and Biochemistry

Publication Details

Published in: New England Journal of Medicine

Volume 373, Issue 1, pp. 48-59

DOI: 10.1056/nejmoa1411481

Field-Weighted Citation Impact: 9.49

Command Palette

Afamelanotide for Erythropoietic Protoporphyria

Authors

Abstract

Topics & Keywords

Publication Details